Literature DB >> 10922226

The role of cervical lymphadenectomy after aggressive concomitant chemoradiotherapy: the feasibility of selective neck dissection.

K M Stenson1, D J Haraf, H Pelzer, W Recant, M S Kies, R R Weichselbaum, E E Vokes.   

Abstract

OBJECTIVES: To evaluate the necessity, technical feasibility, and complication rate of neck dissection performed on patients with head and neck cancer after 5 cycles of concomitant chemoradiotherapy (CRT) and to justify a selective neck dissection (SND) approach and define the optimal timing of post-CRT neck dissection. DESIGN AND
SETTING: Retrospective analysis in an academic university medical center. PATIENTS: Sixty-nine eligible patients with advanced (stage III and IV) head and neck cancer who have undergone 1 of 4 CRT protocols. Patients ranged in age from 36 to 75 years, and surgical procedures were performed over a 4-year period. Follow-up ranged from 6 to 64 months. INTERVENTION: Neck dissection (most commonly unilateral SND) performed within 5 to 17 weeks after CRT completion. MAIN OUTCOME MEASURES: Complication rate and incidence of positive pathology (viable cancer) in pathologic neck dissection specimens.
RESULTS: Seven (10%) of 69 patients developed wound healing complications, 4 (6%) of whom required surgical intervention for ultimate closure. There were no wound infections. Other complications occurred in 11 (16%) of 69 patients and included need for tracheotomy, nerve transection and paresis, and permanent hypocalcemia. Twenty-four (35%) of 69 patients revealed microscopic residual disease. Ten (50%) of 20 patients with N3 neck disease had positive pathology, whereas 14 (36%) of 39 patients with N2 disease had viable carcinoma in the dissection specimen (P =.09 by chi(2) analysis). There was no significant relation between radiologic complete response or partial response and residual microscopic cancer. In 1 patient, disease recurred in the neck after dissection. Mean follow-up time was 30.3 months.
CONCLUSIONS: (1) Neck dissection for patients with N2 or greater neck disease after CRT is necessary to eradicate residual disease. (2) The complication rate of SND after CRT with hyperfractionated radiotherapy is low. (3) SNDs are technically feasible when performed within the "window" between the acute and chronic CRT injury (4-12 weeks). (4) SNDs, rather than more radical procedures, appear to be therapeutically appropriate in this group of patients because of the low incidence of disease recurrence in the neck.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10922226     DOI: 10.1001/archotol.126.8.950

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  25 in total

1.  Prediction of neck dissection requirement after definitive radiotherapy for head-and-neck squamous cell carcinoma.

Authors:  Juliette Thariat; K Kian Ang; Pamela K Allen; Anesa Ahamad; Michelle D Williams; Jeffrey N Myers; Adel K El-Naggar; Lawrence E Ginsberg; David I Rosenthal; Bonnie S Glisson; William H Morrison; Randal S Weber; Adam S Garden
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-03-01       Impact factor: 7.038

Review 2.  Treatment of advanced neck metastases.

Authors:  G Spriano; R Pellini; V Manciocco; P Ruscito
Journal:  Acta Otorhinolaryngol Ital       Date:  2006-12       Impact factor: 2.124

3.  Radical neck dissection: is it still indicated?

Authors:  Marc Hamoir; Carl E Silver; Sandra Schmitz; Robert P Takes; Alessandra Rinaldo; Juan P Rodrigo; K Thomas Robbins; Karen T Pitman; Jesus E Medina; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-10-30       Impact factor: 2.503

Review 4.  The evolving role of selective neck dissection for head and neck squamous cell carcinoma.

Authors:  K Thomas Robbins; Alfio Ferlito; Jatin P Shah; Marc Hamoir; Robert P Takes; Primož Strojan; Avi Khafif; Carl E Silver; Alessandra Rinaldo; Jesus E Medina
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-08-19       Impact factor: 2.503

5.  [(18)F-FDG PET/CT: Image-guided surveillance in advanced head and neck cancer as an alternative to neck dissection].

Authors:  T Derlin
Journal:  Radiologe       Date:  2016-09       Impact factor: 0.635

Review 6.  Positron emission tomography for neck evaluation following definitive treatment with chemoradiotherapy for locoregionally advanced head and neck squamous cell carcinoma.

Authors:  Voichita Bar-Ad; Mark Mishra; Nitin Ohri; Charles Intenzo
Journal:  Rev Recent Clin Trials       Date:  2012-02

7.  Viable tumor in postchemoradiation neck dissection specimens as an indicator of poor outcome.

Authors:  Ian Ganly; Jennifer Bocker; Diane L Carlson; Salvatore D'Arpa; Maria Coleman; Nancy Lee; David G Pfister; Jatin P Shah; Snehal G Patel
Journal:  Head Neck       Date:  2010-11-04       Impact factor: 3.147

8.  "Watch-and-see" policy for the clinically positive neck in head and neck cancer treated with chemoradiotherapy.

Authors:  Akihiro Homma; Yasushi Furuta; Nobuhiko Oridate; Fumiyuki Suzuki; Eisaku Higuchi; Takeshi Nishioka; Hiroki Shirato; Tatsumi Nagahashi; Katsunori Yagi; Satoshi Fukuda
Journal:  Int J Clin Oncol       Date:  2006-12-25       Impact factor: 3.402

9.  Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study.

Authors:  Steven F Powell; Kathryn A Gold; Mark M Gitau; Christopher J Sumey; Michele M Lohr; Steven C McGraw; Ryan K Nowak; Ashley W Jensen; Miran J Blanchard; Christopher D Fischer; Julie Bykowski; Christie A Ellison; Lora J Black; Paul A Thompson; Juan L Callejas-Valera; John H Lee; Ezra E W Cohen; William C Spanos
Journal:  J Clin Oncol       Date:  2020-06-01       Impact factor: 44.544

Review 10.  Efficacy of neck dissection in the management of isolated nodal recurrence after head and neck cancer treatment.

Authors:  Jimmy Yu-wai Chan
Journal:  Curr Oncol Rep       Date:  2013-04       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.